Path, Genocea, and Richard Malley, associate professor of Pediatrics at Children’s Hospital Boston, will collaborate on a protein-subunit pneumococcal vaccine for use in the developing world.
Mark Alderson, director of pneumococcal vaccine project at Path, said: “This collaboration is an example of how nonprofit organizations can work with the private sector to further research that can save millions of lives.
“Genocea’s novel antigen discovery platform technology is designed to identify pneumococcal antigens recognized by critical immune system cells. This technology is an exciting breakthrough in the understanding of cellular immunology that could help Path identify potential new vaccines in the fight against pneumococcus.”